Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 464-471 , December 2008

Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s

  • James H. Stein, MD, FAHA

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, G7/341 CSC (MC 3248), Madison, WI 53792, USA
    • Corresponding Author InformationCorresponding author
    • ,
  • Lauren Komarow, MS

      Affiliations

    • Harvard School of Public Health, Boston, MA, USA
    • ,
  • Bruno R. Cotter, MD

      Affiliations

    • University of California-San Diego, San Diego, CA, USA
    • ,
  • Judith S. Currier, MD

      Affiliations

    • University of California-Los Angeles, Los Angeles, CA, USA
    • ,
  • Michael P. Dubé, MD

      Affiliations

    • Indiana University School of Medicine, Indianapolis, IN, USA
    • ,
  • Carl J. Fichtenbaum, MD

      Affiliations

    • University of Cincinnati Medical Center, Cincinnati, OH, USA
    • ,
  • Mariana Gerschenson, PhD

      Affiliations

    • University of Hawaii, Honolulu, HI, USA
    • ,
  • Carol K.C. Mitchell, PhD

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, G7/341 CSC (MC 3248), Madison, WI 53792, USA
    • ,
  • Robert L. Murphy, MD

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    • ,
  • Kathleen Squires, MD

      Affiliations

    • University of Southern California, Los Angeles, CA, USA
    • ,
  • Robert A. Parker, ScD

      Affiliations

    • Harvard School of Public Health, Boston, MA, USA
    • ,
  • Francesca J. Torriani, MD

      Affiliations

    • University of California-San Diego, San Diego, CA, USA
    • ,
  • ACTG 5152s Study Team

Received 3 June 2008 ,Accepted 16 August 2008.

References 

  1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58
  2. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735
  3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512
  4. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257–262
  5. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006;42:1325–1332
  6. Shankar SS, Dube MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150:933
  7. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045–1052
  8. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–1427
  9. Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007;44:506–517
  10. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484–1492
  11. Haubrich R, Riddler S, DiRenzo G, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infection, February 25–28, 2007, Los Angeles, CA. Abstract 38.
  12. Smith K, Weinberg W, DeJesus E, et al. Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtrictabine (FTC) in antiretroviral-naive HIV-1 infected patients: 24-week results from COL103952 (ALERT). In: Program and Abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2006, San Francisco, CA. Abstract H-1670a.
  13. Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44:540–550
  14. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in HIV-infected antiretroviral naive subjects before and after starting potent antiretroviral therapy: AIDS Clinical Trials Group Study 5152s. J Am Coll Cardiol. 2008;52:569–576
  15. Riddler SA, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. ACTG 5142. Toronto, Canada: 16th International AIDS Conference; 2006;August 13-18, Abstract THLB0204
  16. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–870
  17. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381–387
  18. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5:339–349
  19. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930–1937
  20. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22:1175–1180
  21. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–1563
  22. Schmitz M, Michl GM, Walli R, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;26:225–235
  23. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407–2414
  24. Badiou S, De Boever CM, Dupuy AM, Baillat V, Cristol JP, Reynes J. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen. AIDS. 2003;17:772–774
  25. Sankatsing R, Franssen R, Hassink E, et al. Nevirapine increases high density lipoprotein-cholesterol by stimulation of apolipoprotein A-I synthesis. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, July 22–25, 2007. Abstract WEPEB120LB.

PII: S1933-2874(08)00781-2

doi: 10.1016/j.jacl.2008.08.442

Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 464-471 , December 2008

Article Tools